Introduction to U.S. Measles Trends
U.S. measles cases by year reflect the interplay between vaccination coverage, importation risk, and population susceptibility. Before widespread vaccination, measles was nearly universal in childhood, producing large, predictable waves. After introduction of the measles vaccine in 1963 and the two-dose MMR schedule, cases dropped precipitously, reaching historic lows in the early 2000s. However, outbreaks can reemerge when vaccination rates fall below herd thresholds, underlining the importance of sustained, high coverage. This overview explains patterns in annual case counts, milestones in U.S. control, and how to interpret changes over time.
Measles Before Vaccine and Elimination Status
Prior to 1963, measles was a near-ubiquitous childhood infection with recurrent seasonal peaks. Estimates suggest 3 to 4 million symptomatic cases and 400 to 500 deaths annually in the U.S. The 1963 introduction of inactivated measles vaccine, followed by the safer live-attenuated MMR in 1968, reduced case counts dramatically. In 2000, public health authorities declared measles eliminated from the United States due to the interruption of endemic transmission. Elimination means no continuous chain of spread originating in the U.S., though cases still occur from importations and limited local spread in undervaccinated groups.
Reported U.S. Measles Cases by Year: Data Overview
The following table summarizes notable annual case trends and milestones. Numbers are drawn from CDC surveillance and are rounded to the nearest whole number when applicable. Data are most complete through the most recent finalized report; provisional figures may be updated in subsequent summaries.
| Year | Reported Cases | Key Context |
|---|---|---|
| 1958 | ~763,000 | Reported peak near historical highs; estimates vary by source |
| 1966 | ~3 million (cumulative 1957–1965) | Highlights pre-vaccine burden over a decade |
| 1967 | ~22,000 | Early decline after vaccine introduction |
| 1978 | ~2,500 | Continued downward trend with routine MMR use |
| 1983 | ~1,497 | Lowest reported year at the time |
| 1989–1991 | ~55,000 (1991) | Recent large outbreak associated with undervaccinated preschool children |
| 1992 | ~2,200 | Decline after targeted catch-up campaigns |
| 2000 | ~86 | Reported year of measles elimination |
| 2014 | Highest in 20 years, driven by large multi-state outbreak linked to an amusement venue | |
| 2019 | Highest since 1992; multiple outbreaks in under-vaccinated communities and import-related chains | |
| 2023 | Predominantly import-associated with limited domestic spread |
Interpretation of Year-to-Year Variability
Annual U.S. measles cases fluctuate based on vaccination coverage, susceptibility, and exposure events. Imported cases from regions with ongoing transmission can seed outbreaks in undervaccinated subpopulations, leading to rapid local spread. Clusters often correlate with lower MMR uptake, community misinformation, or access barriers. Public health responses include contact tracing, post-exposure prophylaxis, and targeted vaccination to raise local herd immunity and stop chains of transmission.
Vaccine Impact and Herd Immunity Thresholds
The MMR vaccine is highly effective: two doses are approximately 97% effective against measles. Herd immunity typically requires about 92–95% coverage, depending on population mixing patterns. When coverage falls below this threshold, even localized under-vaccination can permit sustained transmission. Maintaining high two-dose MMR coverage is essential to prevent resurgence, particularly in densely connected communities and environments with frequent international travel.
Current Status and Future Outlook
As of the most recent finalized data, the U.S. reports very low endemic measles burden, with most cases linked to international travel and limited local amplification. Continued monitoring of annual case counts is critical to detect early warning signs of declining coverage. Sustained investment in immunization programs, culturally responsive outreach, and clear communication can preserve elimination and reduce the likelihood of disruptive, large-scale outbreaks.
Key Takeaways: U.S. Measles Cases by Year
- Pre-vaccine era: hundreds of thousands to millions of cases annually with high hospitalization and mortality.
- Post-vaccine introduction: rapid decline, with elimination in 2000 and very low endemic case counts through most years.
- Outbreak-driven peaks: notable increases in 1989–1991 and 2019, often tied to undervaccinated communities and importation.
- 2023 and recent years: low case numbers, largely import-associated, highlighting the value of high vaccine coverage.
- Herd immunity threshold: approximately 92–95% two-dose MMR coverage to prevent sustained transmission.
Conclusion
U.S. measles cases by year illustrate the profound impact of vaccination: from pre-elimination epidemics numbering in the hundreds of thousands to low, mostly imported case counts in well-vaccinated populations. Annual variability is expected and often reflects local coverage gaps and exposure contexts rather than a fundamental breakdown of elimination. Continued vigilance, robust surveillance, and equitable access to MMR vaccination remain central to preventing resurgence and sustaining measles-free status over time.